Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days
Late-breaking data from EHA 2022 present phase 2 results from the first multi-center randomized trial comparing two chemotherapy regimens in Burkitt lymphoma (BL).